Striatal rAAV Delivery Using CED for Widespread Cortical Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for delivering adeno-associated virus (AAV) vectors to the cerebral cortex and striatum are inefficient, limiting widespread expression and treatment efficacy for neurologic disorders.
Innovation Solution
A method involving the administration of recombinant AAV particles, specifically using AAV1 or AAV2 capsids, to the striatum, with convection-enhanced delivery (CED) to ensure distribution to both the striatum and cerebral cortex, including targeted administration to the putamen and caudate nucleus, and optionally using promoters like CBA, CMV, or GUSB to enhance expression in brain cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If simple injection methods are used to deliver AAV vectors to the cerebral cortex, then the procedure is simple and safe, but the distribution of vectors is limited to a 1- to 3-mm radius, preventing widespread expression
Solution Approach 1:
The patent uses convection-enhanced delivery (CED) as an intermediary mechanism between simple injection and widespread distribution. CED employs a delivery catheter system that actively convects the vector solution through brain tissue, enabling distribution beyond the limited diffusion radius of simple injections while maintaining a relatively simple procedural approach
Solution Approach 2:
The patent applies hydraulic principles through convection-enhanced delivery, using pressure gradients and fluid flow dynamics to distribute AAV vectors throughout the cerebral cortex and striatum. The CED system utilizes controlled infusion pressure to overcome tissue resistance and achieve widespread vector distribution
2Area of stationary object
If convection-enhanced delivery (CED) is used to distribute AAV vectors over large distances, then widespread expression is achieved, but the procedure complexity and safety risks increase
Solution Approach 1:
The patent segments the delivery procedure into distinct phases: catheter insertion, real-time MRI monitoring setup, controlled infusion, and post-infusion monitoring. This segmentation allows each step to be optimized and monitored independently, managing overall procedure complexity while achieving widespread vector distribution
Solution Approach 2:
The patent implements real-time MRI monitoring as a feedback mechanism during CED. This allows continuous assessment of vector distribution and delivery parameters, enabling adjustments to maintain safety and efficacy while achieving widespread expression in the cerebral cortex and striatum
3Reliability
If convection-enhanced delivery is used to achieve widespread cortical expression, then treatment efficacy for neurologic disorders is improved, but risks of cannula reflux and infusate leakage increase
Solution Approach 1:
The patent uses real-time MRI monitoring as a feedback system to detect and correct harmful events during CED. The monitoring system identifies cannula reflux and infusate leakage in real-time, allowing immediate intervention to maintain treatment efficacy while minimizing safety risks
Solution Approach 2:
The patent employs reflux-resistant catheter design and controlled infusion parameters as preventive measures before harmful events occur. These precautions cushion against potential reflux and leakage, protecting against safety risks while maintaining the ability to achieve widespread vector distribution for effective neurologic disorder treatment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the safety and efficacy of AAV vector delivery, allowing widespread expression in the cerebral cortex and striatum, thereby improving treatment outcomes for neurologic disorders such as Huntington's and Parkinson's diseases.
Implementation Method 1
The underlying principle of CED involves pumping infusate into brain parenchyma under sufficient pressure to overcome the hydrostatic pressure of interstitial fluid, thereby forcing the infused particles into close contact with the dense perivasculature of the brain. Pulsation of these vessels acts as a pump, distributing the particles over large distances throughout the parenchyma
Implementation Method 2
the rAAV particle undergoes retrograde or anterograde transport in the cerebral cortex
Data Source
AI summary
Provided herein are novel methods for delivering recombinant adeno-associated viral (rAAV) particles to the central nervous system of a mammal (e.g., a human). In aspects, the methods involve administering rAAV particles containing a heterologous nucleic acid to the striatum and causing expression of the heterologous nucleic acid in at least the cerebral cortex and the striatum of the mammal.